Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells. - Wikidata - awgldk - TriplyDB

Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells.

Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells.

http://www.wikidata.org/entity/Q37079170

about

Epigenetic Changes in Endothelial Progenitors as a Possible Cellular Basis for Glycemic Memory in Diabetic Vascular Complications TGF-beta1-induced plasminogen activator inhibitor-1 expression in vascular smooth muscle cells requires pp60(c-src)/EGFR(Y845) and Rho/ROCK signaling.Rho-kinase inhibition acutely augments blood flow in focal cerebral ischemia via endothelial mechanisms Hyperglycemia modulates plasminogen activator inhibitor-1 expression and aortic diameter in experimental aortic aneurysm disease.Increased leukocyte rho kinase (ROCK) activity and endothelial dysfunction in cigarette smokers Sulforaphane inhibits TNF-α-induced adhesion molecule expression through the Rho A/ROCK/NF-κB signaling pathway.Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis.RhoA/Rho-kinase and vascular diseases: what is the link?Involvement of RhoA/ROCK1 signaling pathway in hyperglycemia-induced microvascular endothelial dysfunction in diabetic retinopathy Emerging roles of the myocardin family of proteins in lipid and glucose metabolism.Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease.Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study Rho kinase as a therapeutic target in cardiovascular disease.The Cell Adhesion Molecule Necl-4/CADM4 Serves as a Novel Regulator for Contact Inhibition of Cell Movement and Proliferation.Role of Rho kinase isoforms in murine allergic airway responses.Involvement of Rho-associated protein kinase (ROCK) and bone morphogenetic protein-binding endothelial cell precursor-derived regulator (BMPER) in high glucose-increased alkaline phosphatase expression and activity in human coronary artery smooth mu Gender difference in rat aorta vasodilation after acute exposure to high glucose: involvement of protein kinase C beta and superoxide but not of Rho kinase.Effects and mechanism of moderate aerobic exercise on impaired fasting glucose improvement Physiological role of ROCKs in the cardiovascular system ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury FHL2 prevents cardiac hypertrophy in mice with cardiac-specific deletion of ROCK2.Prevention of diabetes-induced arginase activation and vascular dysfunction by Rho kinase (ROCK) knockout.Atherosclerosis in diabetes and insulin resistance.Rho kinase (ROCK) inhibitors.Does it matter whether or not a lipid-lowering agent inhibits Rho kinase?Critical role of sphingosine-1-phosphate receptor 2 (S1PR2) in acute vascular inflammation.Increased Rho kinase activity in a Taiwanese population with metabolic syndrome.Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease.Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event.Statins inhibit Rho kinase activity in patients with atherosclerosis.Rho-associated kinase activity, endothelial function, and cardiovascular risk factors.The pericyte: cellular regulator of microvascular blood flow Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.Revisited and revised: is RhoA always a villain in cardiac pathophysiology?Long-term diabetic complications may be ameliorated by targeting Rho kinase.Endothelial dysfunction and hypertension in aging.RhoA/mDia-1/profilin-1 signaling targets microvascular endothelial dysfunction in diabetic retinopathy.PKC-β exacerbates in vitro brain barrier damage in hyperglycemic settings via regulation of RhoA/Rho-kinase/MLC2 pathway Effects of systemic inhibition of Rho kinase on blood pressure and renal haemodynamics in diabetic rats.N-acetylcysteine attenuates systemic platelet activation and cerebral vessel thrombosis in diabetes.

P2860

Q26859263-8139326A-61D0-43DE-9CE9-D7AD35FEFF88 Q30440157-01611A0E-3326-428A-A9E1-68EAA3980308 Q33260026-A0120EA3-5CF5-4F46-8BE1-D6043FE78D98 Q34001108-0870DC4B-4155-41E9-B418-3D914B0A65FE Q34088790-18BD439B-4653-4FCB-B954-1C0C360ECA76 Q34290991-7E75F042-9904-453C-865E-66BE7879C920 Q34362144-A68DAD57-04F4-452C-A230-1F2292F41273 Q34378293-F4BCCBBC-4899-40D8-B3A7-A5DB5EED1F83 Q34501845-0B49A8FE-1A1D-4366-AD5B-23869E7F96AC Q34521411-2300F971-4620-46DA-8990-A09DDBBE94CC Q34823543-72FCDF74-E901-44DF-9A65-BF1BEFB8B0CD Q35088730-DF476FA5-DFCC-4D9F-BC65-C54E038EBA0B Q35352722-58399056-40E0-4D40-B3F8-E2F3952FBF39 Q35609836-C857390E-1CF6-4E1F-B00D-DC2D5417D86A Q35687203-D289F779-7A54-4EC6-B156-E6CE0055EEF7 Q35945951-A3A79EC9-0BF0-432B-AA18-DF090B7C308B Q36248761-BDE4E0F6-B1AE-44A0-A9A5-48CD43CB96A9 Q36344151-DC4E950E-5666-4197-9E35-CE6B484C5376 Q36392528-EC5629B2-4E87-41AE-B758-8DE674EF83C2 Q36540884-F6A24895-F136-4AA6-84E2-C4F5CBF1AADC Q36710880-9D2920D6-B96F-4BD7-BCD4-772C91BA4FDB Q36787307-5DBE871E-C910-4542-AFDA-0664667C6DB5 Q36857541-953C369B-9649-4003-92A3-97E02BAF5F26 Q36897945-E382E80E-7842-4F34-A2A8-817E05954913 Q37000895-F96F16BF-E673-4519-A5DD-7732BCA77375 Q37026776-27E779F2-10EF-4126-A2E9-ED18BAE83FF5 Q37041722-2335FA64-1B89-4B14-887B-9C0EDFA9C598 Q37151565-F024F36C-DFC4-415F-901F-A099C0464A9D Q37170931-A0327574-4821-471C-B913-07B3EE8271E6 Q37279038-628008B0-1354-4456-819D-BBEC07664987 Q37367339-68149F8C-2562-4C6C-A344-B629169FBEFB Q37424313-0D485D68-0BAE-4A10-BA33-55B152522B85 Q37450106-047D5687-0E07-4BAC-927D-453DD7F3331E Q37766125-9328DAFC-9A02-405E-AEE1-F7E7EFE23346 Q37838899-189A64AA-9F69-4926-B3AC-53AF737608CC Q38042870-3FE2EC64-65B4-4149-9E55-56DA66FFA458 Q38384340-42F568F9-C028-45D6-BF4B-38E83FB0EEEC Q39107503-DCA15116-556C-451C-9389-B0CB625E38C8 Q41539692-5481FF5A-F195-4178-882A-9A7938DF4491 Q41927946-A1F1A55E-2F52-4F3C-973A-5D737041FA88

P2860

Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells.

http://www.wikidata.org/entity/Q37079170

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 13 June 2005

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Rho-kinase mediates hyperglyce ...... in vascular endothelial cells.

@en

Rho-kinase mediates hyperglyce ...... in vascular endothelial cells.

@nl

type

label

Rho-kinase mediates hyperglyce ...... in vascular endothelial cells.

@en

Rho-kinase mediates hyperglyce ...... in vascular endothelial cells.

@nl

prefLabel

Rho-kinase mediates hyperglyce ...... in vascular endothelial cells.

@en

Rho-kinase mediates hyperglyce ...... in vascular endothelial cells.

@nl

P1433

Q37079170-0340C05B-40A0-4F08-82C4-EA7C9BAD420D

P1476

Q37079170-11B723F0-0B4F-4D2A-A31C-AF7B7AB29FA9

P2093

Q37079170-255E7FD0-C01C-4581-9E9A-3818C34A232E

Q37079170-DC330614-1F7A-462C-A9E2-4C3AF2154768

P2860

Q37079170-18C2588A-D1D6-483C-B4C6-53391624AE52

Q37079170-19327D91-98A3-4936-8189-35FB8317EB0C

Q37079170-30A40636-EF24-4E82-BA0D-A20199E3FF0E

Q37079170-34E1111A-1C09-4858-90AE-AF7DDBF74EBA

Q37079170-37426C53-019E-4799-BC6C-610C5827A0EB

Q37079170-431D8552-2248-4C7B-8792-3294C15C76BA

Q37079170-4901D4EE-1898-4082-B9BA-5944A271085B

Q37079170-49767B4E-EB7B-4502-8AF4-7492CB7517E9

Q37079170-4FBE33A1-D45B-47C3-8D0B-B3B36267987E

Q37079170-52EAD847-BBF1-41D6-A2AA-336281062725

P304

Q37079170-2011C3C1-7343-4900-B811-352E6CB1DF10

P31

Q37079170-4D242F8A-990F-4E0C-8C20-535A5582951B

P356

Q37079170-7976A2A6-DA32-4B07-87BB-BC7F88418794

P407

Q37079170-DE0274E2-6EF4-467C-BE48-864F445A2989

P433

Q37079170-CDADA6CB-28DC-4D23-98C2-27BE05B61F58

P478

Q37079170-37F7D3C4-E464-4625-9232-89B71B6724BF

P577

Q37079170-13CAF427-7AA6-4784-8CEE-34B7C58AAB57

P5875

Q37079170-4F50025D-7533-424F-B87F-0EA0D681002A

P698

Q37079170-7475FD0E-2447-43A4-8BD9-A1BBABEA8C1C

P921

Q37079170-18F31108-07DD-4FE9-85D7-C11DE98E4D08

Q37079170-E23A212E-711D-49BC-BFC8-4A742CBE02F4

P932

Q37079170-0F01E217-4A13-49FD-8F39-1E10431BF2F5

P356

CIRCULATIONAHA.105.534024

P1433

P1476

Rho-kinase mediates hyperglyce ...... in vascular endothelial cells.

@en

P2093

James K Liao

http://www.w3.org/2001/XMLSchema#string

Yoshiyuki Rikitake

http://www.w3.org/2001/XMLSchema#string

P2860

Regulation and functions of Rho-associated kinase

Inhibitory phosphorylation site for Rho-associated kinase on smooth muscle myosin phosphatase

Phosphorylation of the regulatory subunit of smooth muscle protein phosphatase 1M at Thr850 induces its dissociation from myosin

Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase

The pathogenesis of atherosclerosis: a perspective for the 1990s

L-type voltage-gated Ca2+ channels modulate expression of smooth muscle differentiation marker genes via a rho kinase/myocardin/SRF-dependent mechanism.

Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter

Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance.

3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy.

Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis.

P304

3261-3268

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.105.534024

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P577

2005-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7786963

http://www.w3.org/2001/XMLSchema#string

P698

15956119

http://www.w3.org/2001/XMLSchema#string

P921

P932

2633592

http://www.w3.org/2001/XMLSchema#string